Abstract:Accumulating evidence indicates that abnormal deposition of amyloid‐β (Aβ) peptide in the brain is responsible for endothelial cell damage and consequently leads to blood–brain barrier (BBB) leakage. However, the mechanisms underlying BBB disruption are not well described. We employed an monolayer BBB model comprising bEnd.3 cell and found that BBB leakage was induced by treatment with Aβ1–42, and the levels of tight junction (TJ) scaffold proteins (ZO‐1, Claudin‐5, and Occludin) were decreased. Through comparisons of the effects of the different components of Aβ1–42, including monomer (Aβ1–42‐Mono), oligomer (Aβ1–42‐Oligo), and fibril (Aβ1–42‐Fibril), our data confirmed that Aβ1–42‐Oligo is likely to be the most important damage factor that results in TJ damage and BBB leakage in Alzheimer's disease. We found that the incubation of bEnd.3 cells with Aβ1–42 significantly up‐regulated the level of receptor for advanced glycation end‐products (RAGE). Co‐incubation of a polyclonal antibody to RAGE and Aβ1–42‐Oligo in bEnd.3 cells blocked RAGE suppression of Aβ1–42‐Oligo‐induced alterations in TJ scaffold proteins and reversed Aβ1–42‐Oligo‐induced up‐regulation of RAGE, matrix metalloproteinase (MMP)‐2, and MMP‐9. Furthermore, we found that these effects induced by Aβ1–42‐Oligo treatment were effectively suppressed by knockdown of RAGE using small interfering RNA (siRNA) transfection. We also found that GM 6001, a broad‐spectrum MMP inhibitor, partially reversed the Aβ1–42‐Oligo‐induced inhibitor effects in bEnd.3 cells. Thus, these results suggested that RAGE played an important role in Aβ‐induced BBB leakage and alterations of TJ scaffold proteins, through a mechanism that involved up‐regulation of MMP‐2 and MMP‐9. To reveal the role of RAGE in blood–brain barrier (BBB) disruption in Alzheimer's disease (AD), we employed an monolayer BBB model comprising bEnd.3 cell and found that BBB leakage was induced by treatment with amyloid‐β (Aβ), and the levels of tight junction (TJ) scaffold proteins including ZO‐1, Claudin‐5, and Occludin were decreased. Using receptor for advanced glycation end‐products (RAGE) neutralizing polyclonal antibody and siRNA, we confirmed that RAGE played an important role in Aβ‐induced BBB leakage and alterations of TJ scaffold proteins and in the up‐regulation of matrix metalloproteinase‐2 (MMP‐2) and matrix metalloproteinase‐9 (MMP‐9). NF‐κB, nuclear factor kappa‐light‐chain‐enhancer of activated B cells.

A Polypeptide Specifically Binds to RAGE can Alleviate the Destroy of Blood Brain-Barrier caused by Amyloid beta

A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid β peptide-mediated neuronal disorder

RP1, a RAGE antagonist peptide, can improve memory impairment and reduce Aβ plaque load in the APP/PS1 mouse model of Alzheimer's disease

Ginsenoside Rg1 Exerts a Protective Effect Against Aβ₂₅₋₃₅-induced Toxicity in Primary Cultured Rat Cortical Neurons Through the NF-κB/NO Pathway.

The Potential Mechanisms of Aβ-receptor for Advanced Glycation End-Products Interaction Disrupting Tight Junctions of the Blood-Brain Barrier in Alzheimer's Disease.

Targeted inhibition of RAGE reduces amyloid-β influx across the blood-brain barrier and improves cognitive deficits in db/db mice

RAGE Mediates Amyloid-Β Peptide Transport Across the Blood-Brain Barrier and Accumulation in Brain

Aβ1–42 oligomer‐induced leakage in an in vitro blood–brain barrier model is associated with up‐regulation of RAGE and metalloproteinases, and down‐regulation of tight junction scaffold proteins

Aβ1–42 Oligomer Induces Alteration of Tight Junction Scaffold Proteins Via RAGE-mediated Autophagy in Bend.3 Cells

Protective effect of EGb761 against Aβ1-42 -induced SHSY5Y cells injury and blood-brain barrier disruption via regulating Akt/Nrf2 signaling pathway

[Ginsenoside Rg1 antagonizes β-amyloid peptide-induced apoptosis in primarily cultured rat neurons via mitochondrial pathway].

Multivalent Targeting of Blood-Brain Barrier LRP1 for Neurovascular Recovery Therapy for Alzheimer s Disease

RAGE and Alzheimer's disease: a progression factor for amyloid-beta-induced cellular perturbation?

Ginsenoside Rg2 alleviates astrocyte inflammation and ameliorates the permeability of the Alzheimer's disease related blood-brain barrier

Ginsenoside Rg1 Protection Against Β-Amyloid Peptide-Induced Neuronal Apoptosis Via Estrogen Receptor Α and Glucocorticoid Receptor-Dependent Anti-Protein Nitration Pathway.

The Low Density Lipoprotein Receptor-Related Protein 1 Mediates Uptake Of Amyloid Beta Peptides In An In Vitro Model Of The Blood-Brain Barrier Cells

Ginsenoside Rg1 promotes β‑amyloid peptide degradation through inhibition of the ERK/PPARγ phosphorylation pathway in an Alzheimer's disease neuronal model

RPS23RG1 reduces Aβ oligomer-induced synaptic and cognitive deficits

RAGE-AB Interactions in the Pathophysiology of Alzheimer's Disease

Rps23rg1 Reduces A Beta Oligomer-Induced Synaptic And Cognitive Deficits

Protection Induced By Ginsenoside Rb1 in Alzheimer’s Disease Model is Associated With Redressing The Neuronal Hyperexcitability Which is Regulated By Nav1.2 and Nav1.6